AARD
Aardvark Therapeutics, Inc.
Latest Form 4:Purchase$101KbyLee Tien-Li (Chief Executive Officer) · filed Dec 12, 2025
Aardvark Therapeutics, Inc. (AARD) has 7 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Dec 12, 2025.
The most active filer is Chief Executive Officer Lee Tien-Li with 5 filings. Insiders have net bought $450K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Tien-Li Lee
- Employees:40
- HQ:San Diego, CA, US
- IPO:2025-02-13
Insider Buying
$450K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Purchase | 7,000 | $101K | Dec 12 | SEC ↗ | |
Sun NelsonFirst in 3 months | Chief Financial Officer | Purchase | 3,000 | $43K | Dec 12 | SEC ↗ |
| Chief Executive Officer | Purchase | 10,000 | $97K | Sep 16 | SEC ↗ | |
Lee Tien-LiFirst filing | Chief Executive Officer | Purchase | 9,000 | $71K | Sep 12 | SEC ↗ |
Lee Tien-LiFirst filing | Chief Executive Officer | Purchase | 6,000 | $47K | Sep 12 | SEC ↗ |
Lee Tien-LiFirst filing | Chief Executive Officer | Purchase | 5,000 | $43K | Sep 12 | SEC ↗ |
Sun NelsonFirst filing | Chief Financial Officer | Purchase | 6,000 | $48K | Sep 10 | SEC ↗ |
Related companies
Aardvark Therapeutics, Inc. is in the Healthcare sector.